Arkansas is currently home to 726 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Little Rock, Jonesboro, Hot Springs and Fayetteville. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
A Phase 2/3 Study in Adult and Pediatric Participants With SCD
NCT05431088
Recruiting
The purpose of this study is to evaluate the safety, tolerability, efficacy, pharmacokinetics and pharmacodynamics of osivelotor.
Gender:
All
Ages:
Between 6 months and 65 years
Trial Updated:
05/20/2024
Locations: Lynn Institute of the Ozarks, Little Rock, Arkansas
Conditions: Sickle Cell Disease
Register for Updates
A Phase 2 Study to Evaluate the Safety, Tolerability, and Immunogenicity of AFX3772 Vaccine in Healthy Infants
NCT05412030
Recruiting
This is a Phase 2 clinical study to support the use of AFX3772 in healthy infants for the prevention of pneumococcal disease. The purpose of this study is to determine the safety, tolerability, and immunogenicity of 3 different dose levels of AFX3772 compared with PCV13. Infants approximately 2 months of age will be enrolled and receive 4 doses of study vaccine over 8 protocol-defined visits spanning a duration of approximately 18 to 21 months. Part 1 is the dose escalation, lead-in portion of t... Read More
Gender:
All
Ages:
Between 42 days and 90 days
Trial Updated:
05/20/2024
Locations: GSK Investigational Site, Jonesboro, Arkansas
Conditions: Pneumococcal Infections, Pneumonia, Pneumococcal, Pneumonia, Bacterial
Register for Updates
Clinical Trial to Evaluate the Safety and Effectiveness of Using the Tendyne Transcatheter Mitral Valve System for the Treatment of Symptomatic Mitral Regurgitation
NCT03433274
Recruiting
Prospective, controlled, multicenter clinical investigation with four trial cohorts: Randomized, Non-repairable, Severe Mitral Annular Calcification (MAC) and Severe Mitral Annular Calcification Continued Access Protocol (MAC CAP). Subjects in the Randomized cohort will be randomized in a 1:1 ratio to the trial device or to the MitraClip system. Subjects in the Non-repairable, Severe MAC, and Severe MAC CAP cohorts will receive the trial device. The objective of the Clinical Trial to Evaluate t... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
05/20/2024
Locations: Baptist Health Medical Center, Little Rock, Arkansas
Conditions: Mitral Regurgitation, Mitral Insufficiency, Mitral Valve Insufficiency, Cardiovascular Diseases, Valve Disease, Heart, Heart Valve Diseases, Functional Mitral Regurgitation, Degenerative Mitral Valve Disease
Register for Updates
A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes and Inadequate Glycemic Control With Insulin Glargine, With or Without Metformin and/or SGLT-2 Inhibitor
NCT06109311
Recruiting
The main purpose of this study is to determine the safety and efficacy of orforglipron. Participants will have Type 2 Diabetes (T2D) and have inadequate glycemic control with insulin glargine with or without metformin and/or SGLT-2 (sodium-glucose cotransporter-2) inhibitor. The study will last about 46 weeks and may include up to 20 visits.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/19/2024
Locations: SanRo Clinical Research Group, Bryant, Arkansas
Conditions: Type 2 Diabetes
Register for Updates
Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Patients With Metastatic Breast Cancer
NCT05563220
Recruiting
This is a multicenter, Phase 1b/2 trial. The phase 1b part of the trial aims to determine the RP2D of elacestrant when administered in combination with alpelisib, everolimus, palbociclib, abemaciclib, and ribociclib. The Phase 2 part of the trial will evaluate the efficacy and safety of the various combinations in patients with ER+/HER2- advanced/metastatic breast cancer.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/17/2024
Locations: Highlands Oncology Group, Springdale, Arkansas
Conditions: Breast Cancer, Metastatic Breast Cancer
Register for Updates
Left Atrial Appendage Exclusion for Prophylactic Stroke Reduction Trial
NCT05478304
Recruiting
This trial is a prospective, randomized, multicenter, multinational, blinded, superiority trial. The objective of this trial is to evaluate the effectiveness of left atrial appendage exclusion (LAAE) for the prevention of ischemic stroke or systemic arterial embolism in subjects undergoing cardiac surgery who have risk factors for atrial fibrillation and ischemic stroke.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/17/2024
Locations: St. Bernard's Heart & Vascular, Jonesboro, Arkansas
Conditions: Ischemic Stroke, Systemic Embolism
Register for Updates
Optilume PoST AppRoval Clinical Evaluation of Andrology ParaMeters
NCT05383274
Recruiting
Single-arm, prospective study assessing semen quality after treatment with the Optilume Urethral DCB in men between 22 and 65 years of age.
Gender:
Male
Ages:
Between 22 years and 65 years
Trial Updated:
05/17/2024
Locations: Arkansas Urology, Little Rock, Arkansas
Conditions: Urethral Stricture
Register for Updates
Characterization of Pre-Term Neonatal Skin
NCT05127044
Recruiting
The skin of pre-term neonates is not fully developed and often leads to trans-epidermal water loss, trouble regulating temperature, and increased risk of skin wounds. Current treatment decisions are based on subjective, qualitative assessments of the skin. The purpose of this pilot study is to evaluate the utility of non-invasive optical spectroscopy methods to collect key biological information from neonatal skin, including skin maturity, blood oxygenation, and bilirubin content. Parents of pre... Read More
Gender:
All
Ages:
Between 24 hours and 6 months
Trial Updated:
05/17/2024
Locations: University of Arkansas for Medical Sciences, Little Rock, Arkansas
Conditions: Skin Disorder
Register for Updates
AFFINITY DUCHENNE: RGX-202 Gene Therapy in Participants With Duchenne Muscular Dystrophy (DMD)
NCT05693142
Recruiting
RGX-202 is a gene therapy designed to deliver a transgene for a novel microdystrophin that includes functional elements of naturally-occurring dystrophin including the C-Terminal (CT) domain. This is a multicenter, open-label dose evaluation clinical study to assess the safety, tolerability and clinical efficacy of a one-time intravenous (IV) dose of RGX-202 in participants with Duchenne.
Gender:
Male
Ages:
Between 4 years and 11 years
Trial Updated:
05/16/2024
Locations: Arkansas Children's Hospital, Little Rock, Arkansas
Conditions: Duchenne Muscular Dystrophy
Register for Updates
ELACESTRANT in Women and Men With CDK4/6 Inhibitor-Naive Estrogen Receptor Positive, HER-2 Negative Metastatic Breast Cancer Study
NCT05596409
Recruiting
The purpose of this study is to evaluate the efficacy and safety of elacestrant over the course of 6 months in patients with ER+/HER2- advanced/metastatic breast cancer who received no prior CDK4/6i in the metastatic setting.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/16/2024
Locations: Highlands Oncology Group, PA, Springdale, Arkansas
Conditions: Metastatic Breast Cancer
Register for Updates
ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1
NCT05507203
Recruiting
This is a multicenter, randomized, placebo controlled study to evaluate the efficacy and safety of ABX464 given at 25 or 50 mg QD in inducing clinical remission in subjects with moderately to severely active ulcerative colitis who have inadequate response, no response, a loss of response, or an intolerance to either conventional therapies [corticosteroids, immunosuppressant (i.e. azathioprine, 6-mercaptopurine, methotrexate)] and/or advanced therapies [biologics (TNF inhibitors, anti-integrins,... Read More
Gender:
All
Ages:
16 years and above
Trial Updated:
05/16/2024
Locations: University of Arkansas for Medical Sciences, Little Rock, Arkansas
Conditions: Ulcerative Colitis
Register for Updates
ABTECT-2 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -2
NCT05507216
Recruiting
This is a multicenter, randomized, placebo controlled study to evaluate the efficacy and safety of ABX464 given at 25 or 50 mg QD in inducing clinical remission in subjects with moderately to severely active ulcerative colitis who have inadequate response, no response, a loss of response, or an intolerance to either conventional therapies [corticosteroids, immunosuppressant (i.e. azathioprine, 6-mercaptopurine, methotrexate)] and/or advanced therapies [biologics (TNF inhibitors, anti-integrins,... Read More
Gender:
All
Ages:
16 years and above
Trial Updated:
05/16/2024
Locations: Applied Research Center of Arkansas, Little Rock, Arkansas
Conditions: Ulcerative Colitis
Register for Updates